sponsored
PatientsVille.com Logo

PatientsVille

Fexofenadine Medical Research Studies

Up-to-date List of Fexofenadine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Fexofenadine Medical Research Studies

Rank Status Study
1 Not yet recruiting An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects
Condition: Drug Interactions
Interventions: Drug: Fexofenadine;   Drug: Telotristat etiprate
Outcome Measures: Fexofenadine plasma concentration in combination with steady state telotristat etiprate;   Number of treatment emergent adverse events
2 Not yet recruiting Pregabalin for the Treatment of Uremic Pruritus
Condition: Uremic Pruritus
Interventions: Drug: pregabalin 75mg daily for 12 weeks;   Drug: Fexofenadine 60 mg daily for 12 weeks;   Drug: placebo
Outcome Measures: The changes in pruritus symptoms assessed by VAS;   The changes in pruritus score (PS), Skindex-10", "Brief Itching Inventory" and Itch Medical Outcomes Study
3 Unknown  Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis
Condition: Cryptococcosis or Aspergillosis Infections
Intervention: Drug: SPK-843
Outcome Measures: Evaluation of the overall global clinical response;   Evaluate the safety in the administration of SPK-843.
4 Recruiting Age- Versus Ovarian Reserve Markers - Based Therapy in In Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles
Conditions: In Vitro Fertilization;   Ovarian Stimulation
Interventions: Drug: rFSH;   Drug: buserelin
Outcome Measure: The percentage of women with an appropriate number (N=5-14) of retrieved oocytes in IVF/ICSI cycles
5 Recruiting Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
Conditions: Colorectal Cancer;   KRAS Wildtype;   After Resection of Liver Metastases
Interventions: Drug: Folic Acid;   Drug: 5-FU;   Drug: Oxaliplatin;   Drug: Panitumumab
Outcome Measures: Progression Free Survival;   Tolerability and side effects;   Overall Survival
6 Not yet recruiting A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth
Condition: Marijuana Abuse
Interventions: Behavioral: MET;   Behavioral: Mobile self-monitoring;   Behavioral: Motivational feedback messages
Outcome Measures: Marijuana desire;   Marijuana use following trigger exposure;   Frequency of marijuana use;   Percent days abstinent;   Motivation to reduce marijuana use
7 Recruiting Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.
Conditions: B-cell Lymphoid Leukemia;   Young Patients
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Ofatumumab
Outcome Measures: Number of complete responses.;   Number of overall responses.;   Number of patients in progression-free survival.;   Number of patients needing a new CLL Treatment.;   Number of patients in overall survival;   Number of toxic events.;   Outcome of patients according to clinical and biologica variables.
8 Recruiting Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
Condition: Benign Prostatic Hyperplasia
Interventions: Drug: PRX302;   Other: Placebo
Outcome Measures: Efficacy;   Safety
9 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
Outcome Measures: Number of dasatinib permanent discontinuing patients.;   Number of confirmed MR4 and MR4.5.;   Number of stable MR4 and MR4.5 and characteristics.;   Number of Complete Cytogenetic Responses (CCgR);   Number of Major Molecular Response (MMR).;   Number of days to response (CCgR, MMR, MR4, MR4.5).;   Number of overal surviving patients;   Number of progression-free survival patients.;   Number of failure-free survival patients.;   Number of event-free survival patients.;   Number of responses;   Number of responses according to BCR-ABL transcript levels.;   Number of patients with fasting glucose modifications.;   Number of patients with modifications of body mass index during treatment compared to baseline.;   Number of patients with modifications of serum lipids during treatment compared to baseline.;   Patient reported quality of life.;   Number of adverse events.
10 Recruiting NSABP Biospecimen Discovery Project
Condition: Breast Cancer
Interventions: Drug: Paclitaxel;   Biological: trastuzumab
Outcome Measure: Measure variation in biologic response by comprehensive tumor 'omics profiling in patients receiving an upfront regimen containing paclitaxel plus trastuzumab
11 Recruiting Prednisone or Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura
Condition: Nonneoplastic Condition
Interventions: Drug: dexamethasone;   Drug: prednisone;   Procedure: quality-of-life assessment
Outcome Measures: Final response (complete, partial, and minimal response) rate from evaluation of initial response;   Initial response rate;   Quality of response per arm;   Final response rate;   Rate of bleeding events;   Resumed response rate in non-responder patients (at day 42) or patients who have lost response before day 180 from the first evaluation (arm I only);   Time to platelet number increase until a hemostatically effective level is reached and/or disappearance of bleeding symptoms;   Rate of persistent response;   Association of type of initial response with final and persistent response (in patients with final and persistent response);   Rate of rescue interventions;   Rate of splenectomy eligible patients;   Rate of patients who have undergone splenectomy during follow-up;   Rate of patients who develop connective tissue diseases or underlying hematological diseases (myelodysplastic syndromes, chronic lymphoproliferative diseases, others) during follow-up

These studies may lead to new treatments and are adding insight into Fexofenadine etiology and treatment.

A major focus of Fexofenadine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Fexofenadine